GLP-1 (936) amide metabolite suppression of glucose production in isolated mouse hepatocytes

Hormone and Metabolic Research

Volumn 42, Issue 9, 2010, Pages 657-662

  Tomas, E ^a   Stanojevic, V ^a   Habener, J F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

diabetes; hepatic insulin resistance; hyperglycemia

Indexed keywords

GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE 6 PHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); UNCLASSIFIED DRUG; AMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLUCOSE; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CELL ISOLATION; DIABETES MELLITUS; EX VIVO STUDY; GLUCONEOGENESIS; LIVER CELL; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SEPARATION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

AMIDES; ANIMALS; CELL SEPARATION; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCONEOGENESIS; GLUCOSE; GLUCOSE-6-PHOSPHATASE; HEPATOCYTES; MICE; MICE, INBRED C57BL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RECEPTORS, GLUCAGON; RNA, MESSENGER;

EID: 77955028664     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1253421     Document Type: Article

References (30)

1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009 5 262-269
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999 20 876-913
3. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004 36 761-765
4. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009 94 1843-1852
5. Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: A dual receptor hypothesis. Trends Endocrinol Metab 2010 21 59-67
6. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005 289 H2401-H2408
7. Sonne DP, Engstrm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008 146 243-249
8. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008 117 2340-2350
9. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008 478 136-142
10. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, Andersen DK. Glucagon-like peptide-1 (936) amide, cleavage product of glucagon-like peptide-1 (736) is a glucoregulatory peptide. Obesity 2008 16 1501-1509
11. Ayala JE, Bracy DP, James FD, Julien BM, Wasserlman DH, Drucker DJ. The glucagons-like petide-1 receptor regulated endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009 150 1155-1164
12. Nishizawa M, Nakabayashi H, Dawai K, Ito T, Dawakami S, Nakagawa A, Niijima A, Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 2000 80 14-21
13. Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D, Qu L, Cohen DE, Shulman GI, Spiegelman BM. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 2009 58 1499-1508
14. Liu HY, Collins QF, Xiong Y, Moukdar F, Lupo EG Jr, Liu Z, Cao W. Prolonged treatment of primary hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase. J Biol Chem 2007 282 14205-14212
15. Ban K, Kim KH, Cho CK, Sauv M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-Like Peptide (GLP)-1(936)Amide-Mediated Cytoprotection Is Blocked by Exendin(939) Yet Does Not Require the Known GLP-1 Receptor. Endocrinology 2010 151 1520-1531
16. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007 56 1671-1479
17. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007 56 3006-3013
18. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995 358 219-224
19. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996 137 2968-2978
20. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998 141 179-186
21. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S. Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 2009 284 33509-33520
22. Raab EL, Vuguin PM, Stoffers DA, Simmons RA. Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. Am J Physiol Regul Integr Comp Physiol 2009 297 R1785-R1794
23. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006 43 173-181
24. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994 134 2156-2164
25. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J. Glucagon-like peptide-1(736) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 1994 135 2070-2075
26. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ. The glucagon-like peptide-1 metabolite GLP-1-(936) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006 290 E1118-E1123
27. Vahl TP, Paty BW, Fuller BD, Pridgeon RL, DAlession DA. Effects of GLP-1-(737), and GLP-1-(936)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003 88 1772-1779
28. Valverde AM, Burks DJ, Fabregat I, Fisher TL, Carretero J, White MF, Benito M. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 2003 52 2239-2248
29. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007 56 2863-2871
30. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 2002 277 47373-47379